|
Rivamist nasal spray* our lead candidateOur patented rivastigmine nasal spray has good potential to improve the efficacy, tolerability and convenience of this class of drugs known as cholinesterase inhibitors.
We conducted the first human study of nasal absorption of a cholinesterase inhibitor (rivastigmine) and it confirmed the nasal spray could provide a therapeutically effective blood levels of rivastigmine (graph below left). This work also showed the nasal spray produced low metabolite (NAP226-90) levels which helps reduce gastrointestinal side effects (graph below right). *Rivamist™ is an investigational product and neither its use nor the tradename has been approved by the FDA or any other regulatory agency. |
Initial human trial results
Morgan TM, Soh B. Absolute Bioavailability and Safety of a Novel Rivastigmine Nasal Spray in Healthy Elderly Individuals. Br J Clin Pharmacol. 2017 83(3):510-516 PMID: 27639640 DOI: 10.1111/bcp.13133
ANZCTR reference: ACTRN12614001313628
ANZCTR reference: ACTRN12614001313628
Other opportunities
Organophosphorus poisoning treatment
Existing nerve agent antidotes lack sufficient entry to brain so soldiers may be at-risk of post-exposure seizures and neuronal damage. Rivastigmine readily enters the brain so it has potential to treat and/or prevent organophosphorous poisoning.
Agitation associated with Alzheimer's disease
Approximately three million Alzheimer’s disease patients have problems with agitation across the United States, Japan and major European countries. No medications are currently approved for this agitation indication. We have a new, pre-clinical stage combination nasal spray that includes both rivastigmine and dextromethorphan in the same nasal spray bottle.
Important note: All the drug candidates above are not yet approved by any regulatory agency for commercial sale and use in humans in any country, territory or jurisdiction.
Existing nerve agent antidotes lack sufficient entry to brain so soldiers may be at-risk of post-exposure seizures and neuronal damage. Rivastigmine readily enters the brain so it has potential to treat and/or prevent organophosphorous poisoning.
Agitation associated with Alzheimer's disease
Approximately three million Alzheimer’s disease patients have problems with agitation across the United States, Japan and major European countries. No medications are currently approved for this agitation indication. We have a new, pre-clinical stage combination nasal spray that includes both rivastigmine and dextromethorphan in the same nasal spray bottle.
Important note: All the drug candidates above are not yet approved by any regulatory agency for commercial sale and use in humans in any country, territory or jurisdiction.